Vertex, Inc. (NASDAQ:VERX – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the thirteen research firms that are currently covering the company, MarketBeat.com reports.

Fintel reports that on February 28, 2025, Stifel downgraded their outlook for Vertex (NasdaqGM:VERX) from Buy to Hold.

The stock's rise snapped a four-day losing streak.

In Vermont, no day goes by without another news story about the lack of affordable, workforce, and senior housing.

Private foundations providing support, resources, and advocacy for individuals and families affected by rare diseases have ...

We recently compiled a list of the 10 Stocks Drop by Double Digits Mostly Due to Disappointing Earnings. In this article, we ...

BMO Capital analyst Daniel Jester lowered the firm’s price target on Vertex (VERX) to $41 from $56 and keeps a Market Perform rating on the ...

Baird lowered the firm’s price target on Vertex (VERX) to $45 from $62 and keeps an Outperform rating on the shares. The firm updated its model ...

Arc'teryx’s new footwear models will be available globally, launching throughout 2025. The Norvan LD 4 arrives in March, ...

Arc’teryx has introduced four new technical models to its footwear roster: Norvan LD 4, Vertex Speed, Norvan Nivalis, Konseal ...

Vertex shares fell 15.4% after the company posted in-line Q4 results but disappointing Q1 2025 guidance. Adjusted earnings ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective ...